Related Experiment Video
Updated: May 3, 2026
07:46
Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
Published on: June 18, 2018
11.6K
Glucocerebrosidase is shaking up the synucleinopathies
Marina Siebert1, Ellen Sidransky, Wendy Westbroek
11 Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Building 35 Room 1A213, 35 Convent Drive, MSC 3708, Bethesda, MD 20892-3708, USA.
Brain : a Journal of Neurology
|February 18, 2014
Summary
Gaucher disease, a genetic disorder affecting glucocerebrosidase, is linked to Parkinson's disease. Understanding this connection may reveal new therapeutic targets for neurodegenerative disorders.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Background:
- Gaucher disease results from glucocerebrosidase deficiency, leading to substrate accumulation.
- This lysosomal storage disorder has diverse clinical presentations.
- A link exists between glucocerebrosidase gene mutations and synucleinopathies like Parkinson's disease.
Purpose of the Study:
- To review the cellular relationship between glucocerebrosidase and alpha-synuclein.
- To explore therapeutic potential of Gaucher disease treatments for synucleinopathies.
- To discuss the role of lysosomal pathways in neurodegeneration.
Main Methods:
- Literature review of recent studies.
- Analysis of cellular and molecular mechanisms.
- Examination of therapeutic strategies.
Main Results:
- Established link between glucocerebrosidase function and alpha-synuclein.
- Potential for repurposed Gaucher disease therapies in synucleinopathies.
- Lysosomal dysfunction implicated in neurodegenerative pathogenesis.
Conclusions:
- The glucocerebrosidase-alpha-synuclein axis is crucial for neurodegenerative disease understanding.
- Targeting lysosomal pathways offers novel therapeutic avenues.
- Further research into Gaucher disease therapeutics could benefit Parkinson's disease patients.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28
01:21Huntington Disease l: Introduction
110
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
110
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
03:03Amyloid Fibrils
5.2K
5.2K